 |
 |
 |
 |
 |
 |
News from SGC
Posted on Friday 12th of June 2015
In their most recent issue of Show me the Evidence, the Canadian Institutes for Health Research (CIHR) included a feature piece on SGG's research in an interview with SGC-Toronto's Chief Scientist, Dr Cheryl Arrowsmith.
Posted on Monday 25th of May 2015
Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) join forces with small and medium-sized enterprise (SMEs) as well as universities and hospitals in an Innovative Medicines Initiative (IMI) supported public private partnership, ULTRA-DD. In this project, we aim to define and validate new drug targets in inflammatory and auto-immune diseases by testing high quality chemical probes and antibodies in patient-cell derived assays to facilitate a greater understanding of disease pathology.
Posted on Wednesday 13th of May 2015
Recent article on Nature Biotechnology highlights SGC’s new open access initiative to use human cell for target validation.
Link: http://www.nature.com/nbt/journal/v33/n5/full/nbt0515-436.html?WT.ec_id=NBT-201505
Posted on Wednesday 13th of May 2015
Chas Bountra, SGC Oxford’s Chief Scientist and Professor of Translational Medicine at the University of Oxford, is a guest on Will Gompertz’s BBC radio show to discuss how SGC and Oxford scientists are contributing to the development of new and affordable medicines for diseases such as dementia.
http://www.bbc.co.uk/programmes/p02q9w8w (interview starts at 1:08:52)
Posted on Friday 17th of April 2015
Toronto, ON (April 17th, 2015) - The Structural Genomics Consortium (SGC) at the University of Toronto and the Ontario Brain Institute (OBI) have entered into an “open-source” research partnership with two Toronto-based hospitals to test tool compounds, called chemical probes, against epigenetic proteins in research models of Rett syndrome.
Posted on Friday 3rd of April 2015
The question of how nerves sense touch, pressure and pain has been a long standing question in physiology. Also the question of how drugs can affect the nerve’s ability to feel pain is critical for design of drugs that will influence our perception of pain. In order to understand how we sense pressure and pain, Assoc. Prof. Liz Carpenter’s group at the SGC, in collaboration with Assoc. Prof. Stephen Tucker in Physics and Prof. Mark Sansom in Biochemistry have looked at a family of human ion channels. These are proteins in nerve membranes that are sensitive to stimuli such as the stretching of a membrane, thus allowing nerves to detect stretch.
Posted on Thursday 2nd of April 2015
SGC scientists come from countries all over the world to do drug discovery research at our laboratories in Canada, UK and Brazil.
Watch videos of SGC members talking about SGC science and open access in 27 different languages like Arabic, Mandarin, Portuguese and Russian, to name a few: http://www.thesgc.org/sgclanguages
SGC’s open access policy of sharing knowledge and research results without restrictions has helped accelerate the discovery of new medicines for many debilitating diseases such as cancer.
Posted on Tuesday 10th of March 2015
Posted on Tuesday 10th of March 2015
Open-access research into drug discovery has arrived in South America, with a ground-breaking collaboration between leading scientists in North America, Europe and Brazil to provide completely free and open research results to the world.
A $4.3-million (USD) grant from the São Paulo Research Foundation (FAPESP) plus an in-kind contribution of US$ 1.9 million by The University of Campinas (UNICAMP), totalling US$ 6,2 million, will establish Brazil’s first open-access research facility, the Protein Kinase Chemical Biology Centre at the UNICAMP in Brazil.
Posted on Friday 27th of February 2015
Fibrodysplasia ossificans progressiva (FOP) is one of the rarest and most disabling genetic conditions known. The University of Oxford is one of the few places in the world where this disease is being researched, with support from donations.
Pages
